Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glucose + potassium chloride + sodium chloride is a hypotonic intravenous maintenance fluid solution used to treat or prevent dehydration and electrolyte imbalances in hospitalized pediatric patients. It is a combination of three active ingredients: glucose, which serves as an energy source; sodium chloride, which provides sodium and chloride electrolytes; and potassium chloride, which provides potassium. This formulation is designed to maintain fluid and electrolyte homeostasis, specifically plasma sodium, potassium, and glucose levels, in acutely ill children requiring intravenous fluid therapy. In a Phase 4 randomized controlled trial (NCT02926989) conducted by Oulu University Hospital, this hypotonic solution was evaluated as a comparator against an isotonic fluid (Plasma-Lyte Glucose 5%) to assess the risk of hypokalemia, hyponatremia, and other fluid-related outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucose + potassium chloride + sodium chloride.